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NMDA receptors (NMDAR) are glutamate-gated calcium channels that play pivotal roles
in fundamental aspects of neuronal function. Dysregulated receptor function contributes
to many disorders. Recruitment by NMDARs of calcium-dependent enzyme nNOS via
PSD95 is seen as a key contributor to neuronal dysfunction. nNOS adaptor protein
(NOS1AP), originally described as a competitor of PSD95:nNOS interaction, is regarded
an inhibitor of NMDAR-driven nNOS function. In conditions of NMDAR hyperactivity such
as excitotoxicity, one expects NOS1AP to be neuroprotective. Conditions of NMDAR
hypoactivity, as thought to occur in schizophrenia, might be exacerbated by NOS1AP.
Indeed GWAS have implicated NOS1AP and nNOS in schizophrenia. Several studies now
indicate NOS1AP can mediate rather than inhibit NMDAR/nNOS-dependent responses,
including excitotoxic signaling. Yet the concept of NOS1AP as an inhibitor of nNOS
predominates in studies of human disease genetics. Here we review the experimental
evidence to evaluate this apparent controversy, consider whether the known functions of
NOS1AP might defend neurons against NMDAR dysregulation and highlight specific areas
for future investigation to shed light on the functions of this adaptor protein.
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NOS1AP AND DISEASE
The nos1ap gene is linked to diseases including schizophrenia
(Brzustowicz et al., 2004; Xu et al., 2005), post-traumatic stress
disorder and depression (Lawford et al., 2013), autism (Delorme
et al., 2010), sudden cardiac death and long QT syndromes
(Newton-Cheh et al., 2009; Kapoor et al., 2014) and diabetes
(Becker et al., 2008). The gene encodes NOS1 Adaptor Pro-
tein (NOS1AP), initially called carboxy-terminal PSD95-Dlg-ZO1
(PDZ) ligand of nNOS (CAPON; Jaffrey et al., 1998) because it
binds the N-terminal PDZ-containing region of nNOS. The pro-
tein contains a C-terminal class II PDZ-motif (ψxψ-COOH) and
an N-terminal phosphotyrosine binding (PTB) domain but no
other recognizable domains. NOS1AP was originally described as
an inhibitor of NMDA receptor (NMDAR)-driven nNOS actions
because in cell-free assays it reduced interaction between nNOS
and PSD95, the protein recruiting nNOS to NMDAR (Jaffrey
et al., 1998). In contrast, later studies suggested NOS1AP mediates
NMDAR-driven actions of nNOS (Fang et al., 2000; Cheah et al.,
2006; Li et al., 2013). Nevertheless, in human disease studies,
NOS1AP continues to be described as an inhibitor of nNOS
(Eastwood, 2005; Xu et al., 2005; Qin et al., 2010; Weber et al.,
2014). Despite this disparity of views, a consensus is emerging that
nNOS:NOS1AP interaction is a potential drug target for neuro-
logical and cardiovascular disorders (Li et al., 2013; Kapoor et al.,
2014; Weber et al., 2014). The rapidly accumulating reports link-
ing NOS1AP to psychiatric and cardiovascular diseases increase
focus on the druggability of NOS1AP functions. We therefore
believe it is timely to discuss models for NOS1AP regulation of
NMDAR-driven nNOS signaling.
NMDAR-DRIVEN nNOS SIGNALING AND THE INVOLVEMENT
OF PSD95
To address the possible significance of NOS1AP regulation of
NMDAR-driven nNOS functions, we briefly overview the rela-
tionship of nNOS to NMDAR signaling. NMDARs regulate neu-
ronal development, survival and physiology but also contribute to
neuronal dysfunction and disease, from stroke and neurodegen-
erative disorders to psychiatric disorders and chronic pain (Kemp
and McKernan, 2002; Salter and Pitcher, 2012; Citrome, 2014).
NMDAR signaling through nNOS contributes to excitotoxicity
and thus lesions in both stroke and neurodegenerative diseases
(Aarts et al., 2002; Lai et al., 2014), while atrophy caused by exci-
totoxicity may contribute to depression (Rajashekaran et al., 2013;
Vu and Aizenstein, 2013; Stein et al., 2014). NMDAR signaling
attracts interest as a potential therapeutic target because inhibitors
of steps in the pathway from NMDAR to nNOS are effec-
tive in models of many disorders (Kemp and McKernan, 2002;
Hashimoto, 2009; Doucet et al., 2012; Mellone and Gardoni, 2013;
Lai et al., 2014; Mukherjee et al., 2014). However, side-effects of
NMDAR antagonists have limited their clinical potential. After
decades of disappointing results in clinical trials targeting the
NMDAR and calcium influx, 2012 saw the first successful stroke
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trail targeting the signaling pathway downstream from NMDAR
activation and calcium influx (Hill et al., 2012).
The interaction between NMDARs and nNOS is well under-
stood. NMDARs gate flux of calcium as well as sodium across
the plasma membrane, and sustained activation of the recep-
tor leads to substantially increased intracellular concentrations
of both ions in neurons (Courtney and Nicholls, 1992). It is
calcium/calmodulin that activates nNOS. nNOS has long been
recognized as a major player in disorders from excitotoxic lesions
to chronic pain (Florio et al., 2009; Mukherjee et al., 2014),
but catalytic inhibitors have yet to benefit patients. Perhaps they
would not be tolerated given the physiological importance of
nNOS and other isoforms in the heart, vasculature and other
sites. Importantly, calcium influx alone does not strongly acti-
vate nNOS; PSD95 is necessary to efficiently couple NMDAR-
gated calcium influx to nNOS activation (Christopherson et al.,
1999; Aarts et al., 2002; Ishii et al., 2006). The ternary com-
plex assembling NMDAR, PSD95 (or related MAGUKs) and
nNOS was characterized over 15 years ago (Christopherson
et al., 1999; recently reviewed in Doucet et al., 2012) and
has become particular interesting for development of thera-
peutic agents. Protein interactions have recently emerged as
viable druggable targets, even in the most challenging condi-
tions (Blazer and Neubig, 2009; Hill et al., 2012), and may
provide alternative more selective approaches than inhibiting
nNOS or NMDAR directly. Clearly, understanding interactions
between proteins is essential for optimal development of novel
drug leads that target protein-protein interactions, which could
contribute to new treatments for clinically relevant conditions
such as stroke, schizophrenia, chronic pain and cardiovascular
diseases.
Key events downstream of NMDAR-evoked nNOS activation
of relevance to neuronal disorders have remained rather nebulous.
Substantial evidence supports a role for nNOS in excitotoxicity,
but discrepancies exist. In hippocampal slices for example, µM of
exogenous NO had no deleterious effects while excitotoxic stress
was found to only generate 1000-fold lower concentrations of NO
as measured by in situ assay (Keynes et al., 2004). NO generated by
nNOS may reach high concentrations in the immediate vicinity
of the active NMDAR/nNOS complex, but even a micrometer
from the complex, diffusion and metabolism would considerably
lower [NO] (Keynes et al., 2004; Philippides et al., 2005). The
average cellular [NO] may therefore appear below the threshold
for regulation of most NO targets. In such a scenario, interactions
of nNOS with target proteins become critical determinants of
downstream actions of the limited amounts of NO generated (Li
et al., 2013).
SIGNALING PROTEINS DOWNSTREAM OF nNOS
Candidate downstream mediators of nNOS include p38MAPK
and JNKs. Both are involved in disorders including neurode-
generation, cerebral ischemia and chronic pain (reviewed in Ji
et al., 2009; Lai et al., 2014). Activation of p38MAPK in neu-
rons is induced by NO, generated either from donors (Ghatan
et al., 2000) or NMDAR-stimulation (Cao et al., 2005; Soriano
et al., 2008; Li et al., 2013). JNK activation, not an obligate
component of excitotoxicity (Cao et al., 2004; note isoforms may
be regulated in opposite ways, Brecht et al., 2005), may involve
distinct pathways (Soriano et al., 2008). NO can even inhibit JNK
via S-nitrosylation (Park et al., 2000). NMDAR-driven nNOS acti-
vation may be specifically coupled to p38MAPK responses (Cao
et al., 2005; Soriano et al., 2008) via NOS1AP (Li et al., 2013).
NMDAR stimulation recruits NOS1AP to nNOS in neuronal
cells and siRNAs targeting NOS1AP inhibits excitotoxic death
and p38MAPK activation (Li et al., 2013). Moreover, a peptide
designed to selectively disrupt the binding of nNOS to NOS1AP
inhibits both p38MAPK and cell death/lesions in ex vivo and in
vivo excitotoxicity models. Cell death was also prevented by over-
expression of the nNOS-PDZ binding pocket without reducing
calcium or nitric oxide responses. This suggests that competition
for NOS1AP:nNOS interaction can be achieved by targeting either
one or other side of the interaction i.e., providing either nNOS
ligand peptide or the free nNOS ligand-binding domain, thereby
inhibiting events downstream of PSD95:nNOS interaction. The
observation that NOS1AP contributes to nNOS-dependent cell
death is significant as it potentially expands the range of druggable
targets in multiple disorders. However, this conclusion appears
controversial as NOS1AP was originally described as a competi-
tive inhibitor of nNOS function, and continues to be referred to
as such, even though several other studies suggest that NOS1AP
in fact mediates actions of NMDAR-driven nNOS (see Section
NOS1AP and disease). To address this controversy, here we review
how NOS1AP might contribute to NMDAR signaling pathways,
taking into account the structural motifs critical for interactions
between these three proteins. We discuss previously proposed
models and develop for consideration an additional model of
nNOS/PSD95/NOS1AP function that is more consistent with
experimental findings.
REGULATION OF nNOS INTERACTIONS
THE EXCLUSION MODEL
The N-terminal region of nNOS that binds both PSD95
and NOS1AP contains a PDZ domain followed by additional
sequences. PDZ domains are conserved 90 amino acid regions
typically recognizing short C-terminal peptide motifs (Doyle
et al., 1996). Some PDZ domains, like in nNOS, have flanking
sequences or extensions which may confer additional properties,
but these are not part of the core PDZ domain (Wang et al.,
2010). The canonical PDZ interaction involves the docking of
the last three residues at the extreme C-terminus of the peptide
ligand into a “binding pocket” formed between β-sheet 2 and
α-helix 2 of the PDZ domain (Doyle et al., 1996; Harris and
Lim, 2001). The interaction between nNOS and PSD95 is unlike
this canonical PDZ interaction. The initial finding that the N-
terminal region of nNOS (containing a PDZ domain) interacts
with a PDZ domain of PSD95 was taken to indicate that core
PDZ domains could form a dimer, instead of merely binding C-
terminal peptides. The only known interaction site at the time was
the ligand-binding pocket, so PDZ dimerization was thought to
exclude binding of C-terminal ligands (Jaffrey et al., 1998). We
refer to this original concept as the Exclusion Model (Figure 1A).
Consistent with this, recombinant NOS1AP C-terminus inhibits
the interactions between nNOS and PSD95 interaction, both by
GST-PSD95 pull-down of nNOS from 293T cell lysates and by
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FIGURE 1 | Alternative models of NOS1AP interaction with nNOS and
their anticipated consequences to exposure of NOS1AP effector to nitric
oxide. (A) The Exclusion Model, based on Jaffrey et al. (1998) and Eastwood
(2005). Binding of PSD95 to nNOS excludes binding of NOS1AP by PDZ-PDZ
interaction and direct competition and vice versa. A PDZ-PDZ interaction was
originally envisioned (Jaffrey et al., 1998), but this is consistent neither with
structural nor functional data. Coupling of nNOS to NMDAR/Ca2+-influx is
important for activation (Aarts et al., 2002; Ishii et al., 2006). Therefore in all
schemes nNOS, when coupled to NMDAR (via PSD95) is shown producing
NO (active), whereas nNOS displaced from NMDAR/Ca2+-influx (red shading)
is depicted without NO production. In this model the nNOS/NOS1AP
complexes with effectors such as DexRas would not be directly localized to
the receptor and calcium influx-associated NO produced. (B) The Scaffold
Model, based on Christopherson et al. (1999) and Li et al. (2013). Binding of
nNOS β-finger to PSD95 facilitates an extended complex incorporating
NOS1AP (or other ligands with C-terminal motifs). This model places nNOS
close to the source of calcium influx, and NOS1AP effectors close to NO
produced. This is consistent with NOS1AP mediating actions of NMDAR
activated nNOS (Fang et al., 2000; Cheah et al., 2006; Li et al., 2013). But it is
not consistent with cell-free experiments in which NOS1AP competes with
PSD95 for binding nNOS (Jaffrey et al., 1998). (C) The Two-state model. The
extended PDZ domain of nNOS is proposed to exist in two conformational
states. One can bind PSD95 not NOS1AP, the other NOS1AP not PSD95. This
could explain competition between PSD95 and NOS1AP. This model,
however, places the nNOS-NOS1AP complex at a distance from the NMDA
receptor, limiting activation of nNOS in the nNOS-NOS1AP complex. This is
not consistent with NOS1AP mediating NMDAR/nNOS-dependent pathways
(Fang et al., 2000; Cheah et al., 2006; Li et al., 2013). (D) The Delayed-release
model. Here NOS1AP can interact with the unoccupied PDZ pocket seen in
Figure 2, allowing the coupling of NMDAR/nNOS signaling to NOS1AP
dependent pathways. But undefined mechanisms gradually lead to the loss of
PSD95 binding by the beta-finger, presumably via conformational changes,
resulting in delayed dissociation of the nNOS-NOS1AP complex from the
receptor. In this model, the nNOS/NOS1AP effector complex is localized with
the receptor and associated calcium influx for a limited time only. This model
potentially explains the apparently conflicting data on NOS1AP function.
co-immunoprecipitation of PSD95 with nNOS from 293T cells
overexpressing nNOS, PSD95 and NOS1AP (Jaffrey et al., 1998).
Thus nNOS:PSD95 interaction was seen as a dimerization of core
PDZ domains, and nNOS-PDZ ligands like NOS1AP would com-
pete with PSD95 for interaction i.e., the dimerization occludes
both ligand-binding pockets (Figure 1A).
THE SCAFFOLD MODEL
Subsequent structural studies clearly showed the core PDZ
domain of nNOS is not itself the binding partner of PSD95-
type PDZ domains (Hillier et al., 1999; Tochio et al., 1999,
2000; Figure 2), directly contradicting the exclusion model. The
core PDZ domains that contain ligand-binding pockets do not
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FIGURE 2 | The nNOS:PSD95 interaction. Projection of crystal structure
1QAV.pdb (Hillier et al., 1999) of the nNOS extended PDZ domain (left)
docking with a classI PDZ domain (right, from syntrophin in this case). The
parallel β-sheet 2/α-helix 2 regions that form the ligand binding pockets of
the PDZ domains are labelled in each domain. The β finger of the nNOS
extended PDZ that docks in the classI PDZ domain is shown in brown,
revealing that the PDZ ligand binding pocket of nNOS (arrow, left) remains
unoccupied. This projection was generated with Accelrys Discovery Studio.
interact (Christopherson et al., 1999). Instead, the flanking motif
outside the core nNOS PDZ domain, known as the β-finger,
mediates the interaction with PSD95-type PDZ domains. Thus
nNOS:PSD95 is a heterodimer in which each protein contains
one or more PDZ domains (Figure 2). Although not the PDZ
dimer originally envisaged (Figure 1A), this dimeric interaction is
still not a canonical PDZ domain:C-terminal peptide interaction
and is referred to as a non-canonical PDZ interaction (Lenfant
et al., 2010). Core PDZ domains in some cases form dimers by
domain-swapping (Chen et al., 2008; reviewed in Lee and Zheng,
2010), but dimer formation does not occlude ligand binding
pockets. The revised model (Figure 1B) allows the intriguing
possibility that the ligand-binding pocket of this class III-type
PDZ domain remains available for further recruitment of its own
specific targets (Christopherson et al., 1999; Figures 2, 1B, Scaffold
Model).
NOS1AP may be one such target. In contrast to nNOS:PSD95
interaction, the core PDZ domain of nNOS (residues 1–100)
is sufficient to interact with NOS1AP. Furthermore, C-terminal
residues of NOS1AP are required for interaction (Jaffrey et al.,
1998). On this basis, nNOS:NOS1AP binding is a canonical PDZ
interaction. The scaffold model is consistent with this and with
the original data describing the interaction between PSD95 and
the N-terminal region of nNOS (Brenman et al., 1996). However
it conflicts with the observed inhibition of nNOS:PSD95 interac-
tion by NOS1AP C-terminus (Jaffrey et al., 1998) and potentially
other ligands as envisaged in the exclusion model.
THE TWO-STATE MODEL
Although the behavior of NOS1AP in cell-free systems is
inconsistent with the scaffold model, peptide ligands for
nNOS-PDZ terminating with the motif G(D/E) × V did not
inhibit nNOS:PSD95 interaction and YAGQWGESV peptide co-
precipitated in a ternary complex with nNOS and PSD95-PDZ2
(Christopherson et al., 1999; Li et al., 2013). Notably, inhibition
of PSD95:nNOS interaction by NOS1AP has been assumed to be
competitive, but this was not demonstrated (Jaffrey et al., 1998).
Inhibition could instead be non-competitive or allosteric. If the
C-terminal peptide of NOS1AP would dock in the nNOS-PDZ
binding pocket in a manner distinct from non-inhibitory peptides
mentioned above, stabilizing an allosteric change of conformation
that precludes PSD95 from binding the beta-finger of nNOS,
this could explain the inhibition of PSD95:nNOS interaction by
NOS1AP. We call this the Two-State Model (Figure 1C).
However, the Zhang lab specifically considered this in their
NMR spectroscopy study but found no evidence to support it.
They noted that NOS1AP peptide does not compete with PSD95
and concluded NOS1AP was “unlikely to compete with PSD-
95 for nNOS” (Tochio et al., 1999). The two-state model pre-
dicts that events increasing nNOS-NOS1AP interaction should be
accompanied by reduced nNOS-PSD95 interaction. Acquisition
of a distinct conformation of nNOS driven by NMDAR activ-
ity might cause release from PSD95, and explain the increased
nNOS:NOS1AP interaction and consequential downstream sig-
naling reported (Li et al., 2013). However, PSD95-nNOS co-
immunoprecipitation increases upon excitotoxic stimulation in
neuronal cultures, hippocampal slices and ischemic brain (Zhou
et al., 2010). Furthermore, the laboratory that discovered the
inhibition of nNOS:PSD95 interaction by NOS1AP later pro-
posed NOS1AP mediates NMDAR-driven nitrosylation and acti-
vation of NOS1AP ligand DexRas (Fang et al., 2000), which
participates in NMDA-evoked activation of iron uptake (Cheah
et al., 2006). The two-state model (Figure 1C) is not consistent
with this, as nNOS/NOS1AP complexes do not interact with the
NMDAR/PSD95 complex gating calcium influx (Figure 1C) and
yet proximity of nNOS with NMDAR is considered important
for nNOS activation and downstream functions (Cao et al., 2005;
Ishii et al., 2006; Soriano et al., 2008; Li et al., 2013). Indeed, so
important that inhibiting this interaction is a valid and success-
ful strategy for neuroprotection from NMDAR/nNOS-dependent
toxicity (Aarts et al., 2002; Hill et al., 2012).
THE DELAYED-RELEASE MODEL
Here we formulate an alternative model which proposes that
competition with PSD95 observed in cell-free conditions (that
utilize prolonged incubations) does occur in intact systems but
only after a delay. The PDZ ligand-binding pocket of nNOS
is clearly separate from the beta-finger ligand of nNOS that
binds PSD95 (Figure 2), and docking of ligand in the pocket
itself was reported not to affect the beta finger structure (Tochio
et al., 2000). Thus any competition between NOS1AP and PSD95
necessitates secondary allosteric alteration of the nNOS:PSD95
interface. This may not necessarily take place instantaneously. Sig-
naling downstream of nNOS, such as p38MAPK activation, shows
transient activation in stimulated cells (Cao et al., 2005) and
therefore possesses an obligate inhibitory or normalization phase.
Perhaps NOS1AP, in the cellular context, acts as an inhibitor of
nNOS:PSD95 interaction only after a delay, to shut down signal-
ing once it has been activated. This delayed-release model, shown
in Figure 1D, might explain the coupling of NOS1AP effectors to
NMDAR-driven nNOS activation and the opportunities to inhibit
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signaling by competition at the nNOS-PDZ domain. This may be
the most attractive model as it can reconcile most if not all appar-
ently conflicting experimental observations. Currently however,
no experimental evidence directly supports such a sequence of
events nor are there any known mechanisms to explain how this
might occur.
NOS1AP—INHIBITOR OR MEDIATOR?
NOS1AP was regarded as an inhibitor of nNOS function (Jaffrey
et al., 1998), particularly when discussing the possible relevance of
NOS1AP to human disease (Xu et al., 2005; Qin et al., 2010; Weber
et al., 2014). However, functional studies suggest NOS1AP is a
mediator of nNOS signaling and contributor to NMDAR/nNOS-
dependent regulation of neuronal functions (Fang et al., 2000;
Cheah et al., 2006). Decreased expression of NOS1AP by RNAi
or peptide competitors of nNOS:NOS1AP interaction inhib-
ited NMDAR/nNOS-evoked events in neurons (Li et al., 2013).
Notably, NOS1AP competition of nNOS:PSD95 interaction has
been demonstrated entirely in cell-free experiments and no actual
evidence of functional inhibition of nNOS has actually been
reported (Jaffrey et al., 1998). Importantly, NOS1AP does not
directly inhibit the enzyme activity of nNOS (Jaffrey et al.,
1998). Inhibition of NMDAR-evoked nNOS activity has merely
been inferred from its ability to inhibit PSD95:nNOS interac-
tion in cell-free systems. In contrast, evidence for NOS1AP as
a facilitator of nNOS-mediated NMDAR signaling to activation
of DexRas, iron transport, p38MAPK and neurodegeneration
derives from intact cells and animal models (Fang et al., 2000;
Cheah et al., 2006; Li et al., 2013). Similarly, the effects of
NOS1AP on neurite architecture are reduced by nNOS inhibitor
L-NAME (Carrel et al., 2009). This supports the role of NOS1AP
as a positive mediator of nNOS signaling. Apparent discrep-
ancies may arise from differences between cell-free and more
physiological systems used. Additional components or dynamic
properties (like the proposed delayed release, Figure 1D) of
intact neuronal environments absent from those cell-free binding
experiments showing inhibition by NOS1AP of nNOS:PSD95
interaction are among the possible contributing factors. The
evidence for NOS1AP mediating NMDAR/nNOS signaling in
intact systems is therefore more convincing than evidence to the
contrary.
FUTURE PERSPECTIVES FOR NOS1AP RESEARCH
The potential of nNOS:NOS1AP interaction as a candidate drug
target for neurological and cardiovascular disorders (Li et al.,
2013; Kapoor et al., 2014; Weber et al., 2014) highlights the
need to address a number of issues. Is NOS1AP interaction
with nNOS more complex than assumed (e.g., Figure 1D)?
How is interaction between NOS1AP and nNOS regulated? Does
NOS1AP have functions independent of nNOS, for which tar-
geting nNOS:NOS1AP interaction may be irrelevant or even
potentiating? Most challenging perhaps, do functions differ under
conditions of health, in response to trauma or stress, during
disease? Is it more desirable to promote or disrupt NOS1AP
function? Ultimately does NOS1AP act as the inhibitor originally
envisioned, playing a role in self-defence of the neuron against
excessive input to nNOS signaling?
Pre-conditioning should also be considered. While p38MAPK
mediates excitotoxicity, paradoxically it also facilitates the resis-
tance to toxic insults preceded by prior sub-toxic stimuli, in brain
and tissues such as heart and liver (Hausenloy and Yellon, 2006;
Alchera et al., 2010; Zhao et al., 2013). As NOS1AP mediates
NMDAR-evoked p38MAPK activation (Li et al., 2013), does it
also contribute to pre-conditioning pathways? Should the same
question be addressed for NMDAR:PSD95 and PSD95:nNOS
interactions, which are considered as therapeutic targets, and for
NR2B and extra-synaptic NMDARs which are much discussed as
contributors to excitotoxic pathways (Hardingham and Bading,
2010) and may be preferentially linked to p38MAPK activation
(Dau et al., 2014)?
Clearly more work is required to understand the impact of
NOS1AP on NMDAR-driven nNOS signaling pathways, both
at the molecular level as well as in a range of translational
models for those diseases and conditions urgently needing
new therapeutic approaches, including neurodegenerative dis-
eases, stroke, chronic pain, as well as depression and other
psychiatric conditions. Only then can we determine whether
we should seek to boost endogenous functions of NOS1AP
or to inhibit its function to achieve desirable therapeutic out-
comes.
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